Oral Cancer Drugs Deserve Parity
There have been some legislative efforts to bring parity to oral cancer drugs so that insurance companies treat them the same way as injectable cancer drugs.
The American Cancer Society takes a cautious approach to oral parity. Stephen Finan, senior director of policy for the American Cancer Society Cancer Action Network, said in an e-mail that the group is monitoring the issue "to better understand how health plans are handling coverage for both oral and injectable treatments -- specifically to make sure that affordability isn't challenged through increased premiums, stricter utilization management tools or exclusion of anti-cancer medications from formularies to contain costs."
Margaret Dick Tocknell is a reporter/editor with HealthLeaders Media.
- CMS to Speak with ICD-10 Backers Tuesday
- Boston Marathon Bombing Yields Lessons for Hospitals
- Governor Details Healthcare Payment Reform Path in Arkansas
- Reform Puts Vise Grips on Physicians
- Hospital Groups Back NQF Report on Patient Sociodemographics
- MetroHealth Revs Its Population Health Engine
- Medicare Opt-Out a Viable Physician Strategy
- Providers Lag as Consumers Set Agenda
- NPP Demand Rising Under Value-Based Care Models
- HIX Success Could Generate Add-On Revenue for CT